ProCE Banner Activity

The Art of Multidisciplinary Care for Patients With Metabolic Dysfunction–Associated Steatohepatitis

Podcast Episodes

Tune in to this CCO Medical Specialties podcast episode featuring Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, as they discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapies, and management optimization strategies. 

Released: March 14, 2024

Share

Faculty

Arun B. Jesudian

Arun B. Jesudian, MD

Associate Professor of Clinical Medicine
Director of Liver Quality and Inpatient Liver Services
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Mazen Noureddin

Mazen Noureddin, MD, MHSc

Professor of Medicine
Houston Methodist Hospital
Director 
Houston Research Institute
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC, in partnership with the American Gastroenterological Association (AGA) and Practicing Clinicians Exchange (PCE)

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

AGA

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Disclosure

Primary Author

Arun B. Jesudian, MD

Associate Professor of Clinical Medicine
Director of Liver Quality and Inpatient Liver Services
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Arun B. Jesudian, MD: consultant/advisor/speaker: Dynavax, Salix.

Mazen Noureddin, MD, MHSc

Professor of Medicine
Houston Methodist Hospital
Director 
Houston Research Institute
Houston, Texas

Mazen Noureddin, MD, MHSc: consultant/advisor/speaker: Akero, Alligos, Altimmune, AstraZeneca, Boehringer Ingelheim, Boston Pharma, Cytodyn, GlaxoSmithKline, Lilly, Madrigal, Merck, Novo Nordisk, Sagimet, Takeda, Terns; researcher: Akero, Allergan, Altimmune, Boehringer Ingelheim, Boston Pharma, Bristol Myers Squibb, Conatus, Corcept, Enanta, Galectin, Genfit, Gilead, GlaxoSmithKline, Kowa, Lilly, Madrigal, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking, Zydus; individual publicly traded stocks/stock options: Akero, ChronWell, Cytodyn, Rivus Pharma.